Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of butylphthalide soft capsules for prevention of taxane-induced peripheral neuropathy
CTR20220493Phase 2Active
- Sponsor
- CSPC NBP Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of butylphthalide in peripheral neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), sponsored by CSPC NBP Pharmaceutical. Started Mar 2022; status: active.
02
Drugs
butylphthalide
03
Conditions
peripheral neuropathychemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on CTR20220493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220493.